Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: A report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group

References

• Reiter A, Schrappe M, Parwaresch R, Henze G, Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage. A report of the Berlin – Frankfurt – Münster Group. J Clin Oncol 1995; 13: 359–372
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Tiemann M, Ludwig W F, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a reports of the Berlin – Frankfurt – Münster Group trial NHL-BFM 90. Blood 1999; 94: 3294–3306
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Michon J, Behrendt H, Levwerger G, Frappaz D, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370–3379
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Gerrard M, Michon R, Sposto R, Weston C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–2780
   PubMed Web of Science ®Google Scholar
• Link M P, Weinstein H. Malignant non-Hodgkin lymphomas in children. Principles and Practice of Pediatric Oncology, 5th ed, P A Pizzo, D G Poplack. Lippincott Williams and Wilkins, New York 2006; 722–747
   Google Scholar
• Shimizu H, Kikuchi M, Takaue Y, Utsumi J, Takeda T, Fujimoto T. Improved treatment results of non-Hodgkin's lymphoma in children: a report from the Children's Cancer and Leukemia Study Group of Japan. Int J Hematol 1995; 61: 85–96
   PubMed Web of Science ®Google Scholar
• Ziegler J L. Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. New Engl J Med 1977; 297: 75–80
   PubMed Web of Science ®Google Scholar
• Djerassi I, Kim J S. Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas). Cancer 1976; 38: 1043–1051
   PubMed Web of Science ®Google Scholar
• Olweny C L, Katongole-Mbidde E, Kaddu-Mukasa A, Atine I, Owor R, Lwanga S, et al. Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer 1976; 17: 436–440
   PubMed Web of Science ®Google Scholar
• Anderson J R, Wilson J F, Jenkin D T, Meadows A T, Kersey J, Chilcote R R, et al. Childhood non-Hodgkin's lymphoma. The results of randomized therapeutic trial comparing a 4-drug regimen (COMP) to a 10-drug regimen (SLA2-L2). New Engl J Med 1983; 308: 559–565
   PubMed Web of Science ®Google Scholar
• Patte C, Philip T, Rodary C, Bernard A, Zucker J M, Bernard J L, et al. Improved survival rate in children with stage III and VI B cell NHL and leukemia using a multiagent chemotherapy: results of a study of 114 children from SFOP. J Clin Oncol 1986; 4: 1219–1226
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Yamamoto Y, Katano N, Hirota T, Miyawaki T, Yanase T, et al. Treatment of children with non-Hodgkin's lymphoma with CCLSG NHL 855/890 protocols long-term outcome and incidence of secondary malignancies. [Article in Japanese] Rinsho Ketsueki 1998; 39: 281–289
   PubMedGoogle Scholar
• Murphy S B. Classification, staging and results of treatment of childhood NHL, dissimilarities from lymphoma in adults. Semin Oncol 1980; 7: 332–339
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Hvizdala E V, Berard C, Callihan T, Falletta J, Sabio H, Shuster J J, et al. Nonlymphoblastic lymphoma in children – histology and stage-related response to therapy: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 1189–1195
   PubMed Web of Science ®Google Scholar
• Laver J H, Mahmoud H, Pick T E, Hutchison R E, Weinstein H J, Schwenn M, et al. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 2002; 43: 105–109
   PubMed Web of Science ®Google Scholar
• Laver J H, Kraveka J M, Hutchison R E, Chang M, Kepner J, Schwenn M, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23: 541–547
   PubMed Web of Science ®Google Scholar
• Anderson J, Jenkin D, Wilson J, Kjeldsberg C R, Sposto R, Chilcote R R, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993; 11: 1024–1032
   PubMed Web of Science ®Google Scholar
• Sposto R, Meadows A T, Chilcote R R, Steinherz P G, Kjeldsberg C, Kadin M E, et al. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children's Cancer Group. Med Pediatr Oncol 2001; 37: 432–441
   PubMedGoogle Scholar
• Cairo M S, Krailo M D, Morse M, Hutchinson R J, Harris R E, Kjeldsberg C R, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate (‘Orange’) in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a Children's Cancer Group Report. Leukemia 2002; 16: 594–600
   PubMed Web of Science ®Google Scholar
• Sullivan M P, Brecher M, Ramirez I, Ragab A, Hvizdala E, Pullen J, et al. High-dose cyclophosphamide high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of children. Am J Pediat Hematol Oncol 1991; 13: 288–295
   PubMedGoogle Scholar
• Mora J, Filippa D A, Thaler H T, Polyak T, Cranor M L, Wollner N. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer. Cancer 2000; 88: 186–197
   PubMed Web of Science ®Google Scholar
• Haddy T B, Adde M A, McCalla J, Michon J, Pinkerton R, Sposto R, et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 1998; 16: 2070–2079
   PubMed Web of Science ®Google Scholar
• Dantchev D, Paintrand M, Hayat M, Bourut C, Mathe G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THPADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 1979; 32: 1085–1086
   PubMed Web of Science ®Google Scholar
• Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand J P, Chevallier B, et al. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the clinical screening group of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1993; 29A: 350–354
   PubMed Web of Science ®Google Scholar
• Fujita N, Mitsui T, Mori T, Inada H, Horibe K, Tsurusawa M (2006) Relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of registered cases in Japan. Second International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin's Lymphoma, New York, May, 18 – 202006. Pediatric Blood and Cancer, 861
   Google Scholar